Company

Chipscreen Biosciences Secures NMPA IND Acceptance for CS23546 – Oral Small‑Molecule PD‑L1 Inhibitor Advancing in Relapsed or Refractory Lymphoma
CancerChipscreen Biosciences

Chipscreen Biosciences Secures NMPA IND Acceptance for CS23546 – Oral Small‑Molecule PD‑L1 Inhibitor Advancing in Relapsed or Refractory Lymphoma

Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that its Clinical Trial Application (IND) for CS23546 has been officially accepted by China's National Medical Products Administration (NMPA), clearing the way…

Takeda Launches Oveporexton in Japan and China – Novel Oral OX2R Agonist for Narcolepsy Type 1 Now Commercially Available

Takeda Launches Oveporexton in Japan and China – Novel Oral OX2R Agonist for Narcolepsy Type 1 Now Commercially Available

Northland Biotech's Sedominji Completes First National Shipment – World's First Approved HGF Naked Plasmid Gene Therapy Reaches CLI Patients in Nine Provinces

Northland Biotech’s Sedominji Completes First National Shipment – World’s First Approved HGF Naked Plasmid Gene Therapy Reaches CLI Patients in Nine Provinces

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership
Greater Bay AreaHengrui Pharmaceuticals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Clinical trial approval / initiationHarbour BioMed

Harbour BioMed Receives FDA Clearance for Phase I Trial of Novel B7H4xCD3 Bispecific Antibody HBM7004

Fosun Pharma Secures Exclusive China Rights to InxMed's FAK Inhibitors for Solid Tumor Treatment
CancerFosun Pharmaceutical

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

CAR-TJ&J

Johnson & Johnson Terminates Two CAR-T Development Programs Amid Portfolio Prioritization

Show More